Proof of concept study of cognitive improvement in patients with Alzheimer's disease - Sirocco
Study identifier:D3690C00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multi-centre, double-blind, double-dummy, placebo controlled parallel group randomized phase IIb proof of concept study with 3 oral dose groups of AZD3480 or donepezil during 12 weeks treatment in patients with Alzheimer's Disease
Medical condition
Alzheimer Disease
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD3480, Donepezil
Sex
All
Actual Enrollment
659
Study type
Interventional
Age
60 Years - 85 Years
Date
Study Start Date: 01 Jul 2007
Primary Completion Date: 01 Aug 2008
Study Completion Date: 01 Aug 2008
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| No Intervention: 1 Placebo | - |
| Active Comparator: 2 donepezil | - |
| Experimental: 3 AZD3480 | Drug: AZD3480 3 oral doses |
Contacts
Investigators
Principal Investigator
AstraZeneca AZD3480
AstraZeneca
